Market Cap 3.25B
Revenue (ttm) 218.71M
Net Income (ttm) -113.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -51.99%
Debt to Equity Ratio 0.00
Volume 602,300
Avg Vol 1,188,494
Day's Range N/A - N/A
Shares Out 87.86M
Stochastic %K 100%
Beta -0.10
Analysts Strong Sell
Price Target $52.00

Company Profile

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also o...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 443 6209
Address:
5000 Shoreline Court, Suite 300, South San Francisco, United States
CH_Expat
CH_Expat Aug. 7 at 11:43 AM
$IDYA •2H26: Complete NDA filing for darovasertib in uveal melanoma •2H26: Initiate combo IDE892 with RG6505 (panRAS) •2H26: Clinical update for darovasertib in HLA-A2 positive patients at ESMO •2H26: Clinical update for darovasertib in neoadjuvant primary UM (OptimUM-09 trial) at ESMO •2H26: Hengrui update for IDE849 (DLL3 ADC) at ESMO •4Q26: R&D day •2H26: IDE849 Ph1/2 US clinical update •2H26: IDE034 Ph1/2 clinical update I expect great result after great result and a stock price of 2b EV.
1 · Reply
CH_Expat
CH_Expat Aug. 6 at 1:46 PM
$IDYA Fake anchor zone to make you bail.
0 · Reply
DasBrinkus
DasBrinkus Aug. 4 at 12:01 PM
$IDYA https://www.prnewswire.com/news-releases/ideaya-biosciences-reports-second-quarter-2026-financial-results-and-provides-business-update-302841723.html
0 · Reply
DasBrinkus
DasBrinkus Jul. 27 at 8:03 PM
$IDYA Credit to @RonIsWrong https://ir.ideayabio.com/2026-07-27-IDEAYA-Biosciences-Announces-IDE892,-a-Potential-Best-in-Class-MTA-Cooperative-PRMT5-Inhibitor,-Initiates-Part-2-Monotherapy-Expansion-in-the-Phase-1-2-Study-in-MTAP-Deleted-Pancreatic-and-Lung-Cancers
0 · Reply
Merlintrader
Merlintrader Jul. 27 at 4:24 PM
$IDYA IDEAYA Biosciences: the darovasertib approval trade — and the pipeline the market may still be underpricing https://www.merlintrader.com/ideaya-biosciences-stock-hub/
0 · Reply
STACKD0E
STACKD0E Jul. 27 at 11:02 AM
0 · Reply
CH_Expat
CH_Expat Jul. 24 at 4:03 PM
$IDYA Very unusual stock price behavior since the opening bell. Just saying. Probably to myself only.
2 · Reply
kkun
kkun Jul. 23 at 7:42 PM
$IDYA ready for the next leg up!!
0 · Reply
CH_Expat
CH_Expat Jul. 23 at 11:08 AM
$IDYA Adding zone 28-30. $MLYS Adding zone 23-24 Candidates at lower prices: CLDX, TRVI, NRIX, IVA, SNDX, KURA Candidates at much lower prices: COGT, CELC Horror-All-Star-Trash-Team: ALT, SLS, TNXP, CADL, CAPR
4 · Reply
CH_Expat
CH_Expat Jul. 20 at 1:51 PM
$IDYA At this levels, not even all indiciations for Daro are priced in. None is 892, 849 and 034. Not to mention the others. Boreout range here before the magic begins. Yujiro leading BOD also tells me he wants clean track to sell in 2027 or 2028. If CRNX can go for 10b, IDYA can do the same.
1 · Reply
Latest News on IDYA
Ideaya Biosciences reports Q2 EPS ($1.22), consensus ($1.05)

2026-08-04T11:36:19.000Z - 5 days ago

Ideaya Biosciences reports Q2 EPS ($1.22), consensus ($1.05)


IDEAYA Biosciences Earnings release: Q2 2026

Aug 4, 2026, 6:00 AM EDT - 5 days ago

IDEAYA Biosciences Earnings release: Q2 2026


IDEAYA Biosciences Quarterly report: Q2 2026

Aug 4, 2026, 6:00 AM EDT - 5 days ago

IDEAYA Biosciences Quarterly report: Q2 2026


IDEAYA Biosciences Slides: Corporate presentation

Aug 3, 2026, 9:00 AM EDT - 6 days ago

IDEAYA Biosciences Slides: Corporate presentation


Ideaya Biosciences elects CEO Yujiro Hata as chairman

2026-06-17T10:35:07.000Z - 7 weeks ago

Ideaya Biosciences elects CEO Yujiro Hata as chairman


Ideaya Biosciences enrolls first patient in IDE892 trial

2026-06-15T10:05:59.000Z - 7 weeks ago

Ideaya Biosciences enrolls first patient in IDE892 trial


IDEAYA Biosciences Slides: Corporate presentation

Jun 12, 2026, 9:00 AM EDT - 2 months ago

IDEAYA Biosciences Slides: Corporate presentation


Ideaya Biosciences 5.56M share Spot Secondary priced at $27.00

2026-06-09T10:15:20.000Z - 2 months ago

Ideaya Biosciences 5.56M share Spot Secondary priced at $27.00


Ideaya Biosciences $300M Spot Secondary re-offered at $27.00

2026-06-08T20:13:05.000Z - 2 months ago

Ideaya Biosciences $300M Spot Secondary re-offered at $27.00


Ideaya Biosciences announces $300M common stock offering

2026-06-08T20:05:34.000Z - 2 months ago

Ideaya Biosciences announces $300M common stock offering


Ideaya Biosciences announces IDE892 collaboration with Roche

2026-06-03T10:09:39.000Z - 2 months ago

Ideaya Biosciences announces IDE892 collaboration with Roche


Ideaya Biosciences management to meet with Cantor

2026-05-26T20:55:08.000Z - 2 months ago

Ideaya Biosciences management to meet with Cantor


IDEAYA Biosciences Slides: Corporate presentation

May 5, 2026, 7:00 AM EDT - 3 months ago

IDEAYA Biosciences Slides: Corporate presentation


Ideaya Biosciences reports Q1 EPS ($1.11), consensus (98c)

2026-05-05T10:23:24.000Z - 3 months ago

Ideaya Biosciences reports Q1 EPS ($1.11), consensus (98c)


IDEAYA Biosciences Earnings release: Q1 2026

May 5, 2026, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences Earnings release: Q1 2026


IDEAYA Biosciences Quarterly report: Q1 2026

May 5, 2026, 6:00 AM EDT - 3 months ago

IDEAYA Biosciences Quarterly report: Q1 2026


IDEAYA Biosciences Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

IDEAYA Biosciences Proxy statement: Proxy filing


IDEAYA Biosciences Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

IDEAYA Biosciences Proxy statement: Proxy filing


IDEAYA Biosciences Transcript: Study result

Apr 13, 2026, 8:00 AM EDT - 4 months ago

IDEAYA Biosciences Transcript: Study result


IDEAYA Biosciences Press release: Study result

Apr 13, 2026, 8:00 AM EDT - 4 months ago

IDEAYA Biosciences Press release: Study result


IDEAYA Biosciences Slides: Study result

Apr 13, 2026, 8:00 AM EDT - 4 months ago

IDEAYA Biosciences Slides: Study result


IDEAYA Biosciences Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 5 months ago

IDEAYA Biosciences Slides: Corporate presentation


IDEAYA Biosciences Transcript: Status update

Feb 23, 2026, 12:00 PM EST - 5 months ago

IDEAYA Biosciences Transcript: Status update


IDEAYA Biosciences Annual report: Q4 2025

Feb 17, 2026, 6:00 AM EST - 6 months ago

IDEAYA Biosciences Annual report: Q4 2025


IDEAYA Biosciences Earnings release: Q4 2025

Feb 17, 2026, 6:00 AM EST - 6 months ago

IDEAYA Biosciences Earnings release: Q4 2025


IDEAYA Biosciences Quarterly report: Q3 2025

Nov 4, 2025, 6:00 AM EST - 9 months ago

IDEAYA Biosciences Quarterly report: Q3 2025


IDEAYA Biosciences Earnings release: Q3 2025

Nov 4, 2025, 6:00 AM EST - 9 months ago

IDEAYA Biosciences Earnings release: Q3 2025


IDEAYA Biosciences Transcript: R&D Day 2025

Sep 8, 2025, 8:00 AM EDT - 11 months ago

IDEAYA Biosciences Transcript: R&D Day 2025


IDEAYA Biosciences Slides: FY 2025

Sep 8, 2025, 8:00 AM EDT - 11 months ago

IDEAYA Biosciences Slides: FY 2025


IDEAYA Biosciences Quarterly report: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences Quarterly report: Q2 2025


IDEAYA Biosciences Earnings release: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 1 year ago

IDEAYA Biosciences Earnings release: Q2 2025


CH_Expat
CH_Expat Aug. 7 at 11:43 AM
$IDYA •2H26: Complete NDA filing for darovasertib in uveal melanoma •2H26: Initiate combo IDE892 with RG6505 (panRAS) •2H26: Clinical update for darovasertib in HLA-A2 positive patients at ESMO •2H26: Clinical update for darovasertib in neoadjuvant primary UM (OptimUM-09 trial) at ESMO •2H26: Hengrui update for IDE849 (DLL3 ADC) at ESMO •4Q26: R&D day •2H26: IDE849 Ph1/2 US clinical update •2H26: IDE034 Ph1/2 clinical update I expect great result after great result and a stock price of 2b EV.
1 · Reply
CH_Expat
CH_Expat Aug. 6 at 1:46 PM
$IDYA Fake anchor zone to make you bail.
0 · Reply
DasBrinkus
DasBrinkus Aug. 4 at 12:01 PM
$IDYA https://www.prnewswire.com/news-releases/ideaya-biosciences-reports-second-quarter-2026-financial-results-and-provides-business-update-302841723.html
0 · Reply
DasBrinkus
DasBrinkus Jul. 27 at 8:03 PM
$IDYA Credit to @RonIsWrong https://ir.ideayabio.com/2026-07-27-IDEAYA-Biosciences-Announces-IDE892,-a-Potential-Best-in-Class-MTA-Cooperative-PRMT5-Inhibitor,-Initiates-Part-2-Monotherapy-Expansion-in-the-Phase-1-2-Study-in-MTAP-Deleted-Pancreatic-and-Lung-Cancers
0 · Reply
Merlintrader
Merlintrader Jul. 27 at 4:24 PM
$IDYA IDEAYA Biosciences: the darovasertib approval trade — and the pipeline the market may still be underpricing https://www.merlintrader.com/ideaya-biosciences-stock-hub/
0 · Reply
STACKD0E
STACKD0E Jul. 27 at 11:02 AM
0 · Reply
CH_Expat
CH_Expat Jul. 24 at 4:03 PM
$IDYA Very unusual stock price behavior since the opening bell. Just saying. Probably to myself only.
2 · Reply
kkun
kkun Jul. 23 at 7:42 PM
$IDYA ready for the next leg up!!
0 · Reply
CH_Expat
CH_Expat Jul. 23 at 11:08 AM
$IDYA Adding zone 28-30. $MLYS Adding zone 23-24 Candidates at lower prices: CLDX, TRVI, NRIX, IVA, SNDX, KURA Candidates at much lower prices: COGT, CELC Horror-All-Star-Trash-Team: ALT, SLS, TNXP, CADL, CAPR
4 · Reply
CH_Expat
CH_Expat Jul. 20 at 1:51 PM
$IDYA At this levels, not even all indiciations for Daro are priced in. None is 892, 849 and 034. Not to mention the others. Boreout range here before the magic begins. Yujiro leading BOD also tells me he wants clean track to sell in 2027 or 2028. If CRNX can go for 10b, IDYA can do the same.
1 · Reply
kkun
kkun Jul. 20 at 2:38 AM
$IDYA ready for the next leg up!!
0 · Reply
Merlintrader
Merlintrader Jul. 17 at 5:49 PM
$IDYA IDEAYA Biosciences: the darovasertib approval trade — and the pipeline the market may still be underpricing https://www.merlintrader.com/ideaya-biosciences-stock-hub/
0 · Reply
STACKD0E
STACKD0E Jul. 17 at 1:16 PM
$XNCR $IDYA ✨️
0 · Reply
CH_Expat
CH_Expat Jul. 17 at 9:48 AM
$IDYA Hunger games. Slow bleed down before the real run begins.
0 · Reply
Nussiisback
Nussiisback Jul. 15 at 6:52 PM
1 · Reply
Quantumup
Quantumup Jul. 13 at 3:46 PM
Cantor reiterated $IMCR at OW—said it Sees Remarkable R/R—Immunocore is finishing up enrollment in TEBE-AM, its Ph3 study of tebentafusp (Kimmtrak, a gp100-targeted TCR bispecific) in 2L cutaneous melanoma. $IDYA $REPL DCTH MRK BMY IOVA NVS RHHBY PFE AMGN IMTX Here's what else Cantor had to say: https://x.com/Quantumup1/status/2076694388005069311?s=20
0 · Reply
Laynester
Laynester Jul. 12 at 6:27 PM
$QNST $IDYA $WK $SGP $BBW Discovered these 5 investment turnaround winners prospecting today, Sunday afternoon... All will be bought and qued up for pre-market at 7am on Monday. Choice bottom upper's, take a look at them, run them through your trend setting analysis, buy or not, if you do, set an alert then [stop] out if it goes low. Stick around if it goes higher. These opportunities are always out there if you look for them. Or you can count on me to point them out for ya. Set a stop. 100%--->🦬
0 · Reply
PensionPulse
PensionPulse Jul. 9 at 3:42 PM
$IDYA Indeed!!
0 · Reply
RonIsWrong
RonIsWrong Jul. 7 at 6:51 PM
$IDYA behaving beautifully here
1 · Reply
CH_Expat
CH_Expat Jul. 7 at 6:00 PM
$IDYA Better sooner than later.
0 · Reply
CDMO
CDMO Jul. 7 at 5:58 PM
$IDYA 40 baby
0 · Reply
sv__
sv__ Jul. 7 at 5:48 PM
$IDYA Whoop Whoop!🙌 Luv it.
0 · Reply